secwatch.observer — SEC 8-K summary
======================================

Issuer:     CEL SCI CORP (CVM)
CIK:        0000725363
Form:       8-K
Filed at:   2026-05-14T21:16:25+00:00
Accession:  0001654954-26-004910
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEL-SCI enters 50/50 revenue-sharing partnership with Amarox for Multikine in Saudi Arabia
--------------------------------------------------------------------------------

- 50%/50% net revenue share for Multikine sales in Saudi Arabia; Amarox exclusive distributor upon SFDA approval.
- Amarox ranked #1 for SFDA critical/unavailable medicine applications for 3 consecutive years (2022-2024).
- Optional extension to GCC countries (Bahrain, Kuwait, Oman, Qatar, UAE). CEL-SCI retains all IP and global rights.
- Partnership targets SFDA Breakthrough Medicine Designation for Multikine in head and neck cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/725363/000165495426004910/0001654954-26-004910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/725363/000165495426004910/cvm_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-26-004910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer